Previous 10 | Next 10 |
VANCOUVER, British Columbia, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2023). Mr. Ia...
2023-11-30 01:52:55 ET More on Xenon Pharma Xenon: MDD Data Provides Rationale For XEN1101 Advancement Towards FOS Xenon Pharmaceuticals: XEN1101 Remains A Gem Despite The Dip Xenon Pharmaceuticals announces proposed public offering Xenon says mid-stage trial...
VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE) (“Xenon”), a neurology-focused biopharmaceutical company, today announced the pricing of its upsized underwritten public offering of 8,461,542 common shares and, in lieu of common...
2023-11-29 16:08:26 ET More on Xenon Pharma Xenon: MDD Data Provides Rationale For XEN1101 Advancement Towards FOS Xenon Pharmaceuticals: XEN1101 Remains A Gem Despite The Dip Xenon Pharmaceuticals Inc. (XENE) Q3 2023 Earnings Call Transcript Xenon says mid-s...
2023-11-28 13:49:13 ET Summary Xenon Pharmaceuticals Inc.'s XEN1101 is being advanced in two identical phase 3 studies known as X-TOLE2 and X-TOLE3 for patients with focal onset seizure; Completion of recruitment for XTOLE-2 expected end of 2024. The global epilepsy market size wi...
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is one of today's top gainers. The company's shares have moved 2.07% on the day to $31.51. Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canad...
2023-11-27 07:38:21 ET More on Xenon Pharma Xenon Pharmaceuticals: XEN1101 Remains A Gem Despite The Dip Xenon Pharmaceuticals Inc. (XENE) Q3 2023 Earnings Call Transcript Xenon Pharmaceuticals: Upcoming Phase Two Major Depressive Disorder Data Readout Represents An ...
VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported topline results from the randomized, double-blind, placebo-controlled, Phase 2 proof-of-concept X-NOVA clinical trial, which evalu...
2023-11-26 04:55:05 ET Summary XEN1101 shows clinical promise in epilepsy and MDD, with Phase 3 trials critical for its broader efficacy evaluation. Financially, Xenon faces a stark YOY revenue drop and rising R&D costs but maintains strong liquidity and cash runway. Marke...
2023-11-09 16:56:54 ET More on Neurocrine Biosciences Neurocrine Biosciences, Inc. (NBIX) Q3 2023 Earnings Call Transcript Neurocrine Biosciences, Inc. 2023 Q3 - Results - Earnings Call Presentation Neurocrine's Crinecerfont Delivered, But The Street Has Been Slow To...
News, Short Squeeze, Breakout and More Instantly...
Xenon Pharmaceuticals Inc. Company Name:
XENE Stock Symbol:
NASDAQ Market:
Xenon Pharmaceuticals Inc. Website:
2024-06-25 17:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-15 18:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
VANCOUVER, British Columbia, June 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the Goldman Sachs 45th Annual Global Healthcare Conference taking place June 10-13, 2024 in M...